Previously, we have examined early indicators of the need to change the antigenic composition of SARS-CoV-2 vaccines, including mutations in the S protein, antigenic characteristics, the ability of the current vaccine to reduce infection and transmission, and the range of clinical manifestations, with the most important being cross-neutralizing activity against circulating and new VOC variants [4]. Here, PROS1 is linked to infection.